-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AP-303 in Diabetic Nephropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AP-303 in Diabetic Nephropathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AP-303 in Diabetic Nephropathy Drug Details: AP-303 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MC-232 in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MC-232 in Hidradenitis Suppurativa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MC-232 in Hidradenitis Suppurativa Drug Details: MC-232 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MC-225 in Vulvar Lichen Sclerosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MC-225 in Vulvar Lichen Sclerosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MC-225 in Vulvar Lichen Sclerosus Drug Details: MC-225 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MC-225 in Uremic (Renal) Pruritus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MC-225 in Uremic (Renal) Pruritus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MC-225 in Uremic (Renal) Pruritus Drug Details: MC-225 is under development...
-
Product Insights
NewUremic (Renal) Pruritus – Drugs In Development, 2024
Empower your strategies with our Uremic (Renal) Pruritus – Drugs In Development, 2024 report and make more profitable business decisions. Uremic pruritis is a condition where there is presence of excess urea in the blood associated with itchiness (pruritis). It is associated with chronic kidney disease (CKD). Most common in end stage CKD and patients on hemodialysis. Underlying diseases (CKD), diabetes, inflammation, uremic toxins are common triggering factors affecting 20-25% of body surface area and is associated with itchiness, secondary skin...
-
Product Insights
NewHidradenitis Suppurativa – Drugs In Development, 2024
Empower your strategies with our Hidradenitis Suppurativa – Drugs In Development, 2024 report and make more profitable business decisions. Hidradenitis suppurativa (HS) is a chronic skin condition that features pea- to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop in areas where skin rubs together, such as the armpits, groin, between the buttocks, and under the breasts. The Hidradenitis Suppurativa drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewPruritus – Drugs In Development, 2024
Empower your strategies with our Pruritus – Drugs In Development, 2024 report and make more profitable business decisions. Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin, and reactions to drugs. Symptoms include redness, bumps, spots or blisters, dry, cracked skin, and leathery or scaly texture to the skin. Risk factors include heat, allergies, asthma, hay fever, hives, and eczema. Treatment includes corticosteroids, antihistamines, and...
-
Product Insights
NewPlaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024
Empower your strategies with our Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024 report and make more profitable business decisions. Plaque psoriasis, also known as psoriasis vulgaris, is the most common form of psoriasis, a chronic skin condition characterized by the rapid buildup of skin cells. It results from an overactive immune system, causing skin cells to accumulate on the surface, forming thick, scaly, and often itchy patches or plaques. These patches can vary in size and typically have a...
-
Product Insights
NewKeratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...
-
Product Insights
NewKeratoconjunctivitis – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities. The Keratoconjunctivitis drugs in development market...